BioProcessors’ SimCell (Tm) Platform Demonstrates Potential To Increase Amgen’s (AMGN) Cell Culture Experiment Capacity 
10/19/2005 5:09:32 PM

An announcement at Biochemical XIV Show disclosed the completion of an important phase of a long-term joint project with Amgen (NASDAQ:AMGN) aimed at evaluating BioProcessors’ SimCell (Tm) MicroBioreactor technology. This technology has the potential to increase Amgen’s mammalian cell culture process development capacity.